Advertisement
Document › Details
Galapagos N.V.. (1/8/19). "Press Release: Sands Capital Reports 5.7% Holding in Galapagos". Mechelen.
Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Sands Capital Management, LLC.
Pursuant to Belgian transparency legislation[1], Galapagos received a transparency notification on 27 December 2018 from Sands Capital Management, LLC, who notified that it held 3,092,264 of Galapagos' voting securities (consisting of American Depository Shares) on 13 September 2018. On this date, Sands Capital Management, LLC, crossed the 5% threshold of Galapagos' voting securities by acquiring additional securities. These 3,092,264 securities represented 6.02% of Galapagos' then outstanding 51,337,763 shares. Since the number of outstanding Galapagos shares currently stands at 54,465,421, the 3,092,264 securities of Sands Capital Management currently represent 5.7%. The full transparency notice is available on the Galapagos website.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com.
Contact
Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784
Sofie Van Gijsel
Director IR
+32 485 19 14 15
ir@glpg.com
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications@glpg.com
[1] Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market.
Record changed: 2023-06-05 |
Advertisement
More documents for Galapagos (Group)
- [1] Adaptimmune Therapeutics plc. (5/30/24). "Press Release: Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future...
- [2] Galapagos N.V.. (9/19/23). "Press Release: Galapagos Appoints Simon Sturge to Its Board of Directors". Mechelen....
- [3] Galapagos N.V.. (6/15/23). "Press Release: Galapagos Appoints Thad Huston as Chief Financial Officer and Chief Operating Officer". Mechelen....
- [4] Galapagos N.V.. (6/12/23). "Pressemitteilung: Galapagos Appoints Dr. Susanne Schaffert as Non-executive Independent Director to Its Board". Mechelen....
- [5] Galapagos N.V.. (6/21/22). "Press Release: Galapagos to Acquire CellPoint and AboundBio to Accelerate Access to Next-generation Cell Therapies". Mechelen, Leiden & Pittsburgh, PA....
- [6] Ryvu Therapeutics S.A.. (3/15/22). "Press Release: Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update". Krakow....
- [7] Galapagos N.V.. (1/26/22). "Press Release: Galapagos Appoints Paul Stoffels as Chief Executive Officer". Mechelen....
- [8] Ryvu Therapeutics S.A.. (12/14/21). "Press Release: Ryvu Announces Option to License Inflammation Program Exercised by Galapagos NV". Tübingen, Houston, TX & New York, NY....
- [9] Galapagos N.V.. (8/30/21). "Press Release: Galapagos Announces Planned Retirement of CEO". Mechelen....
- [10] Galapagos N.V.. (2/10/21). "Press Release: Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF". Foster City, CA & Mechelen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top